Thursday, February 22, 2024

Touchlight receives funding to develop a DNA vaccine platform


Bill & Melinda Gates Foundation grant will boost potential of nanoparticle-formulated doggy bone DNA

Touchlight – a company which focuses on genetic medicine revolution – is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform. Its latest research is being financed by a new grant from the Bill & Melinda Gates Foundation.

The programme aims to reinforce evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce durable T-cell responses following vaccine administration in nanoparticles and strong neutralising antibodies.

In addition, Touchlight will be investigating the performance of doggybone DNA for therapeutic monoclonal antibody production.

If the effectiveness of the doggybone DNA platform is successfully demonstrated in DNA vaccine and gene therapy applications, it has the potential to support the wider global availability of innovative medicines. It will also further the application of the doggybone platform in enabling rapid pandemic response.

Meanwhile, Touchlight’s enzymatic approach is enabling scalable DNA manufacture in a smaller footprint than can be achieved with fermentation-based processes, while also eliminating antibiotic-resistance genes that could be present in plasmid DNA.

Karen Fallen, chief executive officer of Touchlight, explained: “This grant is further evidence of the potential of our doggybone DNA platform. We are excited to start the programme, which could potentially demonstrate that the doggybone DNA platform can support a rapid, scalable, durable and thermostable vaccine solution for future pandemic response.”

Touchlight’s central ambition is to enable genetic medicine by providing contract development and manufacturing services to genetic medicine manufacturers. Doggybone DNA is already widely utilised across the genetic medicine market, in areas such as critical starting material for mRNA vaccine production, DNA vaccine applications and genome editing.

Source: PharmaTimes


Please enter your comment!
Please enter your name here

Related articles

Did you hear Dr. Maya Valecha’s input in the audio from the WHO’s Pandemic Agreement Civil Society Meetings 2024?

Dr Maya Valecha, Gynecologist, MD, by training Social and political activists. Universal Health Organization, Committee member Dr. Maya Valecha, MD(Gynae) based in...

Stock markets snap six-day rally; Sensex slumps over 400 points

Mumbai: Equity benchmark indices Sensex and Nifty broke their six-day winning run on Wednesday and settled with a...

India exported USD 6.65 bn oil products derived from Russian oil to sanctioning nations: Report

New Delhi: Over one-third of India's export of oil products to the G7-led coalition countries was derived from...

India, China hold military talks on Eastern Ladakh border row; no indication of any breakthrough

New Delhi: India and China held a fresh round of high-level military talks to resolve the over three-and-half-year-old...